Literature DB >> 31612402

Establishment of Rabbit Liver VX2 Tumor Model Using Percutaneous Puncture Inoculation of Tumor Fragment Guided and Evaluated by Ultrasonography.

Hui-Ming Yi1, Bao-Huan Cai2, Xi Ai3, Kai-Yan Li1, Wei Zhang4.   

Abstract

The aim of the present study is to evaluate a method of establishing model of rabbit liver VX2 tumor using percutaneous puncture inoculation of tumor fragment guided by ultrasonography. VX2 tumor fragments were implanted into the liver of 13 New Zealand white rabbits flushed by 1 mL normal saline through percutaneous puncture needle guided by ultrasonography. Conventional ultrasonography and contrast-enhanced ultrasonography (CEUS) were performed 14 days after inoculation, and then the rabbits were sacrificed and pathologically examined. The success rate of inoculation was 100%. The average size of liver VX2 tumor was 1.7 cm×1.3 cm, CEUS of VX2 liver tumors showed the "rapid wash-in and wash-out" vascular pattern. There were significant differences between VX2 tumors and liver parenchyma in quantitative parameters of A, k and A × k (P<0.05), which meant that VX2 liver tumors were characterized by more blood flow volume and faster blood velocity than liver parenchyma. Tumor fragment flushed by normal saline into the liver through a needle may be a promising method for the induction of a hepatic tumor. And CEUS can be used for accurately assessing angiogenesis and blood perfusion of VX2 tumors.

Entities:  

Keywords:  VX2 tumor; contrast-enhanced ultrasonography; liver; rabbit; ultrasonography

Mesh:

Substances:

Year:  2019        PMID: 31612402     DOI: 10.1007/s11596-019-2111-6

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  17 in total

1.  Histologic analysis of liver tissue following hepatic arterial infusion of ferromagnetic particles in a rabbit tumour model.

Authors:  Paul Moroz; Cecily Metcalf; Bruce N Gray
Journal:  Biometals       Date:  2003-09       Impact factor: 2.949

Review 2.  Contrast-enhanced ultrasound: what is the evidence and what are the obstacles?

Authors:  Stephanie R Wilson; Lennard D Greenbaum; Barry B Goldberg
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

3.  Two Shope papillomavirus-associated VX2 carcinoma cell lines with different levels of keratinocyte differentiation and transplantability.

Authors:  E Georges; F Breitburd; N Jibard; G Orth
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

4.  Major causes of death among men and women in China.

Authors:  Jiang He; Dongfeng Gu; Xigui Wu; Kristi Reynolds; Xiufang Duan; Chonghua Yao; Jialiang Wang; Chung-Shiuan Chen; Jing Chen; Rachel P Wildman; Michael J Klag; Paul K Whelton
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

5.  Controlled release and antitumor effect of pluronic F127 mixed with cisplatin in a rabbit model.

Authors:  Akinaga Sonoda; Norihisa Nitta; Shinich Ohta; Ayumi Nitta-Seko; Shigehiro Morikawa; Yasuhiko Tabata; Masashi Takahashi; Kiyoshi Murata
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

6.  Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver.

Authors:  Kwang-Hun Lee; Eleni Liapi; Veronica Prieto Ventura; Manon Buijs; Josephina A Vossen; Mustafa Vali; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2008-04-10       Impact factor: 3.464

7.  Contrast-enhanced ultrasonography of the rabbit VX2 tumor model: Analysis of vascular pathology.

Authors:  Yanjun Liu; Weidong Ren; Caigang Liu; Kun Huang; Yueqin Feng; Xuemei Wang; Yuzhang Tong
Journal:  Oncol Lett       Date:  2012-07-24       Impact factor: 2.967

8.  Comparison of hypoxia-inducible factor-1alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors.

Authors:  Sumeet Virmani; Thomas K Rhee; Robert K Ryu; Kent T Sato; Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Barbara Szolc-Kowalska; Gayle E Woloschak; Guang-Yu Yang; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2008-10       Impact factor: 3.464

9.  Percutaneous US-guided radiofrequency ablation with perfused needle applicators: improved survival with the VX2 tumor model in rabbits.

Authors:  Johannes Hänsler; Daniel Neureiter; Milan Wasserburger; Rolf Janka; Thomas Bernatik; Thomas Schneider; Wolfgang Müller; Markus Frieser; Stefan Schaber; Dirk Becker; Eckhart G Hahn; Deike Strobel
Journal:  Radiology       Date:  2003-11-26       Impact factor: 11.105

10.  Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis.

Authors:  Mario Scartozzi; Gianluca Svegliati Baroni; Luca Faloppi; Marzia Di Pietro Paolo; Chiara Pierantoni; Roberto Candelari; Rossana Berardi; Stefania Antognoli; Cinzia Mincarelli; Andrea Risaliti; Cristina Marmorale; Ettore Antico; Antonio Benedetti; Stefano Cascinu
Journal:  J Exp Clin Cancer Res       Date:  2010-12-15
View more
  3 in total

1.  Proton Magnetic Resonance Spectroscopy at 3.0T in Rabbit With VX2 Liver Cancer: Diagnostic Efficacy and Correlations With Tumor Size.

Authors:  Ruikun Liao; Zhuoyue Tang; Xiaojiao Li; Liang Lv; Chao Yang; Hua Xiong; Bi Zhou; Jiayi Yu; Dan Zhang
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

2.  Super-Resolution Ultrasound Localization Microscopy on a Rabbit Liver VX2 Tumor Model: An Initial Feasibility Study.

Authors:  Wei Zhang; Matthew R Lowerison; Zhijie Dong; Rita J Miller; Krista A Keller; Pengfei Song
Journal:  Ultrasound Med Biol       Date:  2021-05-24       Impact factor: 3.694

3.  Early Identification of Residual Tumors following Microwave Ablation Using Contrast-Enhanced Ultrasonography in a Rabbit VX2 Liver Cancer Model.

Authors:  Huiming Yi; Baohuan Cai; Xi Ai; Kaiyan Li; Pengfei Song; Wei Zhang
Journal:  Biomed Res Int       Date:  2020-09-26       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.